BeautyHealth Appoints Philippe Schaison, PharmaD, to Board of Directors
BeautyHealth (NASDAQ: SKIN) appointed Philippe Schaison, PharmaD to its Board of Directors, effective October 30, 2025. Schaison brings over 20 years of leadership across global aesthetics, biotech, and consumer health, including roles as CEO NA of Syneron Candela and President of Allergan Aesthetics, and current CEO of Soltégo, Inc.
He will join the Compensation and Nominating & Corporate Governance Committees. Following the appointment, the Board will total eight directors. The company said Schaison’s experience should help expand Hydrafacial’s global reach and accelerate category growth.
BeautyHealth (NASDAQ: SKIN) ha nominato Philippe Schaison, PharmaD al Consiglio di Amministrazione, con effetto dal 30 ottobre 2025. Schaison porta oltre 20 anni di leadership nei settori estetica globale, biotecnologia e salute dei consumatori, tra ruoli come CEO NA di Syneron Candela e Presidente di Allergan Aesthetics, e attuale CEO di Soltégo, Inc.
Si unirà ai Comitati di Compensazione e di Nominazione & Corporate Governance. Dopo la nomina, il Consiglio sarà composto da otto amministratori. L'azienda ha dichiarato che l'esperienza di Schaison dovrebbe contribuire a espandere la risonanza globale di Hydrafacial e accelerare la crescita della categoria.
BeautyHealth (NASDAQ: SKIN) ha nombrado Philippe Schaison, PharmaD a su Junta Directiva, con efecto a partir del 30 de octubre de 2025. Schaison aporta más de 20 años de liderazgo en estética global, biotecnología y salud del consumidor, incluyendo cargos como CEO NA de Syneron Candela y Presidente de Allergan Aesthetics, y actual CEO de Soltégo, Inc.
Se unirá a los Comités de Compensación y de Nominación y Gobierno Corporativo. Tras la nombración, la Junta estará conformada por ocho directores. La empresa afirmó que la experiencia de Schaison debería ayudar a ampliar el alcance global de Hydrafacial y acelerar el crecimiento de la categoría.
BeautyHealth (NASDAQ: SKIN)은 Philippe Schaison, PharmaD를 이사회에 임명했으며, 발효일은 2025년 10월 30일부터입니다. Schaison은 글로벌 미용, 생명공학 및 소비자 건강 분야에서 20년 이상의 리더십을 보유하고 있으며, Syneron Candela의 북미 CEO 및 Allergan Aesthetics의 사장, 그리고 현재 Soltégo, Inc.의 CEO 등의 경력을 포함합니다.
그는 보상위원회와 선임 및 기업지배구조위원회에 합류합니다. 이 임명으로 이사회는 8명의 이사로 구성될 예정입니다. 회사는 Schaison의 경력이 Hydrafacial의 글로벌 도달 범위를 확장하고 카테고리 성장을 가속화하는 데 도움이 될 것이라고 밝혔습니다.
BeautyHealth (NASDAQ: SKIN) a nommé Philippe Schaison, PharmaD au conseil d'administration, à compter du 30 octobre 2025. Schaison apporte plus de 20 ans d'expérience en leadership dans les domaines de l'esthétique mondiale, de la biotechnologie et de la santé des consommateurs, notamment en tant que CEO NA de Syneron Candela et Président d'Allergan Aesthetics, et actuel CEO de Soltégo, Inc.
Il se joindra aux comités Rémunération et Nominations & Gouvernance d'entreprise. Suite à la nomination, le conseil comptera huit administrateurs. L'entreprise a déclaré que l'expérience de Schaison devrait aider à étendre la portée mondiale de Hydrafacial et accélérer la croissance de la catégorie.
BeautyHealth (NASDAQ: SKIN) hat Philippe Schaison, PharmaD in den Vorstand berufen, mit Wirkung zum 30. Oktober 2025. Schaison bringt über 20 Jahre Führungserfahrung in globalen Bereichen der Ästhetik, Biotechnologie und Konsumentengesundheit mit, darunter Positionen als CEO NA von Syneron Candela und Präsident von Allergan Aesthetics, und derzeit CEO von Soltégo, Inc.
Er wird den Kommissionen Vergütung und Nominierung & Corporate Governance beitreten. Nach der Ernennung wird der Vorstand acht Direktoren umfassen. Das Unternehmen sagte, dass Schaisons Erfahrung dazu beitragen sollte, Hydrafacials globale Reichweite zu erweitern und das Wachstum der Kategorie zu beschleunigen.
BeautyHealth (NASDAQ: SKIN) عيّنت فيليب شيسون، PharmaD في مجلس إدارتها، اعتبارًا من 30 أكتوبر 2025. يجلب شيسون أكثر من 20 عامًا من القيادة في الجمال العالمي والتكنولوجيا الحيوية والرعاية الصحية للمستهلكين، بما في ذلك مناصب كـCEO NA لشركة Syneron Candela ورئيس Allergan Aesthetics، والمنصب الحالي كـCEO لشركة Soltégo, Inc.
سينضم إلى لجنتي التعويض و الترشيح وحوكمة الشركات. بعد التعيين، سيبلغ إجمالي أعضاء المجلس ثمانية أعضاء. قالت الشركة إن خبرة شيسون من شأنها أن تساعد في توسيع نطاق Hydrafacial عالميًا وتسريع نمو الفئة.
- Appointed Philippe Schaison effective Oct 30, 2025
- Adds 20+ years in aesthetics, biotech, and consumer health
- Schaison currently serves as CEO of Soltégo, Inc.
- Joins Compensation and Nominating & Corporate Governance Committees
- Board size increases to eight directors
- None.
Global Aesthetics Leader Brings Deep Industry Expertise and Proven Track Record Driving Growth Across Health, Beauty, and Consumer Sectors
LONG BEACH, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- The BeautyHealth Company (NASDAQ: SKIN), home to flagship brand Hydrafacial, today announced the appointment of global aesthetics leader, Philippe Schaison, PharmaD, to its Board of Directors, effective as of October 30, 2025.
Dr. Schaison has spent over 20 years leading organizations across the global aesthetics, biotech, and consumer health industries. He currently serves as Chief Executive Officer and a director of Soltégo, Inc., a bio-cosmetic company. Previously, Dr. Schaison was Chief Executive Officer NA of Syneron Candela, President of Allergan Aesthetics, and held senior leadership roles at Clarins, Johnson & Johnson, and L’Oréal. Today, Dr. Schaison serves as Chairman of the Board of Raziel Therapeutics Ltd., an Israeli-based biotechnology company, and sits on a number of other biomedical company boards including AIVITA Biomedical, Inc., Dyve Biosciences, Inc., and miraDry, Inc. Dr. Schaison earned an M.B.A. from Hautes Etudes Commerciales in Paris, and a Doctorate in Pharmacy from the Université Paris V René Descartes.
BeautyHealth Executive Chairman Brent Saunders said: “Philippe’s experience scaling global beauty and aesthetics businesses, coupled with his proven ability to drive innovation and profitability, will bring invaluable perspective to the BeautyHealth Board. His deep expertise will help the Company unlock the full potential of the dynamic Hydrafacial brand, elevate our global reach, and accelerate category growth.”
Dr. Schaison fills an open seat on the BeautyHealth Board and will join the Compensation and Nominating & Corporate Governance Committees. Following the appointment, BeautyHealth’s Board will be comprised of eight directors.
About The Beauty Health Company
The Beauty Health Company (NASDAQ: SKIN) is a medtech meets beauty company delivering millions of skin health experiences every year that help consumers reinvent their relationship with their skin, bodies, and self-confidence. Our brands are pioneers: Hydrafacial™ in hydradermabrasion, SkinStylus™ in microneedling, and Keravive™ in scalp health. Together, with our powerful global community of estheticians, partners, and consumers, we are personalizing skin health for all ages, genders, skin tones, and skin types. We are committed to being ever more mindful in how we conduct our business to positively impact our communities and the planet. Find a local provider at https://hydrafacial.com/find-a-provider/ and learn more at beautyhealth.com or LinkedIn.
Contacts:
Investors: IR@beautyhealth.com
Media: press@beautyhealth.com
Source: BeautyHealth
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5e88819a-f590-4e51-a7fe-66872a55b5ef
FAQ
Who did BeautyHealth (SKIN) appoint to its board on November 3, 2025?
What roles will Philippe Schaison hold on the BeautyHealth board (SKIN)?
How many directors will BeautyHealth (SKIN) have after the appointment?
What relevant experience does Philippe Schaison bring to BeautyHealth (SKIN)?
What is Philippe Schaison’s current executive position referenced in the announcement?
